NASDAQ:VRCA

Verrica Pharmaceuticals Competitors

$13.73
+0.32 (+2.39 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$13.60
Now: $13.73
$13.94
50-Day Range
$13.24
MA: $14.81
$17.46
52-Week Range
$6.02
Now: $13.73
$18.42
Volume2,193 shs
Average Volume108,765 shs
Market Capitalization$349.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3

Competitors

Verrica Pharmaceuticals (NASDAQ:VRCA) Vs. TBPH, STTK, CMPS, OLMA, ZYME, and KRON

Should you be buying VRCA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Verrica Pharmaceuticals, including Theravance Biopharma (TBPH), Shattuck Labs (STTK), COMPASS Pathways (CMPS), Olema Pharmaceuticals (OLMA), Zymeworks (ZYME), and Kronos Bio (KRON).

Verrica Pharmaceuticals (NASDAQ:VRCA) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Volatility & Risk

Verrica Pharmaceuticals has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Profitability

This table compares Verrica Pharmaceuticals and Theravance Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verrica PharmaceuticalsN/A-54.53%-40.42%
Theravance Biopharma-345.16%N/A-51.60%

Valuation and Earnings

This table compares Verrica Pharmaceuticals and Theravance Biopharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-12.15
Theravance Biopharma$73.41 million18.91$-236,460,000.00($4.25)-5.01

Verrica Pharmaceuticals has higher earnings, but lower revenue than Theravance Biopharma. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Verrica Pharmaceuticals and Theravance Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verrica Pharmaceuticals01302.75
Theravance Biopharma00703.00

Verrica Pharmaceuticals presently has a consensus price target of $17.75, indicating a potential upside of 29.28%. Theravance Biopharma has a consensus price target of $33.2857, indicating a potential upside of 56.42%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Verrica Pharmaceuticals.

Institutional & Insider Ownership

34.0% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.4% of Theravance Biopharma shares are owned by institutional investors. 40.2% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 5.9% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Theravance Biopharma beats Verrica Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Verrica Pharmaceuticals (NASDAQ:VRCA) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and price targets for Verrica Pharmaceuticals and Shattuck Labs, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verrica Pharmaceuticals01302.75
Shattuck Labs00603.00

Verrica Pharmaceuticals presently has a consensus price target of $17.75, indicating a potential upside of 29.28%. Shattuck Labs has a consensus price target of $45.60, indicating a potential upside of 38.60%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Verrica Pharmaceuticals.

Earnings and Valuation

This table compares Verrica Pharmaceuticals and Shattuck Labs' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-12.15
Shattuck LabsN/AN/AN/AN/AN/A

Insider & Institutional Ownership

34.0% of Verrica Pharmaceuticals shares are held by institutional investors. 40.2% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Verrica Pharmaceuticals and Shattuck Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verrica PharmaceuticalsN/A-54.53%-40.42%
Shattuck LabsN/AN/AN/A

Summary

Shattuck Labs beats Verrica Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Verrica Pharmaceuticals (NASDAQ:VRCA) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Profitability

This table compares Verrica Pharmaceuticals and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verrica PharmaceuticalsN/A-54.53%-40.42%
COMPASS PathwaysN/AN/AN/A

Insider and Institutional Ownership

34.0% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. 40.2% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Verrica Pharmaceuticals and COMPASS Pathways, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verrica Pharmaceuticals01302.75
COMPASS Pathways00603.00

Verrica Pharmaceuticals currently has a consensus target price of $17.75, suggesting a potential upside of 29.28%. COMPASS Pathways has a consensus target price of $70.75, suggesting a potential upside of 98.12%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Verrica Pharmaceuticals.

Earnings and Valuation

This table compares Verrica Pharmaceuticals and COMPASS Pathways' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-12.15
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

Summary

COMPASS Pathways beats Verrica Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Verrica Pharmaceuticals (NASDAQ:VRCA) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Verrica Pharmaceuticals and Olema Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-12.15
Olema PharmaceuticalsN/AN/AN/AN/AN/A

Insider and Institutional Ownership

34.0% of Verrica Pharmaceuticals shares are owned by institutional investors. 40.2% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Verrica Pharmaceuticals and Olema Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verrica Pharmaceuticals01302.75
Olema Pharmaceuticals00403.00

Verrica Pharmaceuticals currently has a consensus price target of $17.75, suggesting a potential upside of 29.28%. Olema Pharmaceuticals has a consensus price target of $60.6667, suggesting a potential upside of 69.13%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Verrica Pharmaceuticals.

Profitability

This table compares Verrica Pharmaceuticals and Olema Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verrica PharmaceuticalsN/A-54.53%-40.42%
Olema PharmaceuticalsN/AN/AN/A

Summary

Olema Pharmaceuticals beats Verrica Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Zymeworks (NYSE:ZYME) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares Zymeworks and Verrica Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zymeworks$29.54 million46.95$-145,440,000.00($3.83)-7.84
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-12.15

Verrica Pharmaceuticals has lower revenue, but higher earnings than Zymeworks. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

75.1% of Zymeworks shares are owned by institutional investors. Comparatively, 34.0% of Verrica Pharmaceuticals shares are owned by institutional investors. 4.2% of Zymeworks shares are owned by company insiders. Comparatively, 40.2% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Zymeworks and Verrica Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zymeworks03712.82
Verrica Pharmaceuticals01302.75

Zymeworks presently has a consensus price target of $51.50, suggesting a potential upside of 71.55%. Verrica Pharmaceuticals has a consensus price target of $17.75, suggesting a potential upside of 29.28%. Given Zymeworks' stronger consensus rating and higher possible upside, research analysts clearly believe Zymeworks is more favorable than Verrica Pharmaceuticals.

Volatility & Risk

Zymeworks has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500.

Profitability

This table compares Zymeworks and Verrica Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zymeworks-569.13%-44.06%-34.36%
Verrica PharmaceuticalsN/A-54.53%-40.42%

Summary

Zymeworks beats Verrica Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Kronos Bio (NASDAQ:KRON) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Kronos Bio and Verrica Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kronos Bio00403.00
Verrica Pharmaceuticals01302.75

Kronos Bio presently has a consensus price target of $43.6667, suggesting a potential upside of 98.30%. Verrica Pharmaceuticals has a consensus price target of $17.75, suggesting a potential upside of 29.28%. Given Kronos Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Kronos Bio is more favorable than Verrica Pharmaceuticals.

Profitability

This table compares Kronos Bio and Verrica Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kronos BioN/AN/AN/A
Verrica PharmaceuticalsN/A-54.53%-40.42%

Valuation and Earnings

This table compares Kronos Bio and Verrica Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/AN/AN/AN/A
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-12.15

Insider and Institutional Ownership

34.0% of Verrica Pharmaceuticals shares are held by institutional investors. 40.2% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Kronos Bio beats Verrica Pharmaceuticals on 5 of the 7 factors compared between the two stocks.


Verrica Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.28+3.3%$1.34 billion$73.41 million-4.50Unusual Options Activity
News Coverage
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.5$32.90+2.4%$1.34 billionN/A0.00Analyst Report
Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.71+1.8%$1.33 billionN/A0.00Analyst Upgrade
OLMA
Olema Pharmaceuticals
1.6$35.87+9.5%$1.30 billionN/A0.00Increase in Short Interest
Zymeworks logo
ZYME
Zymeworks
1.8$30.04+7.1%$1.29 billion$29.54 million-7.97News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$22.02+4.0%$1.28 billionN/A0.00Insider Selling
Unusual Options Activity
Gap Down
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.12+2.2%$1.22 billionN/A-2.73Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.27+3.5%$1.21 billionN/A-19.04
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.46+3.5%$1.21 billion$4.23 million-9.20News Coverage
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$34.53+6.1%$1.20 billionN/A0.00
Innoviva logo
INVA
Innoviva
1.4$11.75+1.0%$1.18 billion$261.02 million5.99
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.14+20.8%$1.17 billionN/A0.00Increase in Short Interest
Lockup Expiration
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.22+0.1%$1.17 billion$59.70 million-192.20
NKTX
Nkarta
1.8$35.83+0.8%$1.17 billionN/A0.00Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.13+1.7%$1.13 billion$35.22 million-7.39
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$25.89+1.2%$1.12 billion$230,000.00-12.04News Coverage
Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.15+5.8%$1.12 billion$42.12 million-12.70Unusual Options Activity
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.71+4.2%$1.11 billionN/A-8.99Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$17.51+0.1%$1.08 billion$111.81 million-7.36
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.14+0.4%$1.08 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.20+3.1%$1.07 billionN/A-6.84
Zogenix logo
ZGNX
Zogenix
1.7$19.41+1.6%$1.06 billion$3.65 million-2.04
MannKind logo
MNKD
MannKind
1.4$4.56+7.7%$1.05 billion$63.04 million-21.71Increase in Short Interest
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.01+4.9%$1.05 billionN/A-8.49Gap Down
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.23+1.5%$1.04 billion$120,000.00-3.79Analyst Upgrade
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$39.85+1.0%$1.04 billion$20.79 million-13.74Analyst Upgrade
News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.71+0.3%$1.04 billionN/A-6.81Increase in Short Interest
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$24.77+2.0%$1.02 billionN/A-8.54
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.71+2.6%$996.70 million$122.47 million-27.86Analyst Downgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.73+5.2%$993.66 million$1.52 million-11.56Increase in Short Interest
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.33+0.2%$982.60 million$800.40 million22.95
Prothena logo
PRTA
Prothena
2.1$23.94+2.4%$934.94 million$810,000.00-9.35Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.27+3.2%$918.28 millionN/A-12.57Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$26.51+2.2%$914.76 millionN/A-24.55
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.44+0.8%$895.14 million$227.19 million45.67
Radius Health logo
RDUS
Radius Health
1.3$19.61+3.6%$886.30 million$173.32 million-8.04Gap Down
Annexon logo
ANNX
Annexon
1.9$23.23+0.8%$879.54 millionN/A0.00Increase in Short Interest
Gap Down
Affimed logo
AFMD
Affimed
1.6$10.33+4.3%$873.54 million$23.96 million-17.51Analyst Report
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.15+1.5%$869.64 millionN/A0.00News Coverage
Gap Down
Merus logo
MRUS
Merus
1.6$23.03+1.7%$863.20 million$31.13 million-7.50Analyst Report
Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.00+1.7%$845.56 millionN/A-10.39
Epizyme logo
EPZM
Epizyme
1.8$8.21+0.2%$833.11 million$23.80 million-3.68
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.41+0.5%$822.01 million$322.36 million124.36
Humanigen logo
HGEN
Humanigen
1.7$15.34+0.8%$813.46 millionN/A0.00Analyst Report
Increase in Short Interest
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$24.04+4.7%$806.52 million$296.70 million49.06Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.19+0.9%$758.12 million$40.89 million-3.51Analyst Report
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.19+0.2%$750.64 million$322.07 million-4.94Decrease in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$27.15+3.5%$732.39 million$148.36 million-7.05News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.43+1.5%$727.39 million$150,000.00-4.90
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.89+1.4%$723.91 million$2.22 million-17.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.